PortfoliosLab logo
Akebia Therapeutics, Inc. (AKBA)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US00972D1054

CUSIP

00972D105

IPO Date

Mar 20, 2014

Highlights

Market Cap

$766.90M

EPS (TTM)

-$0.21

Total Revenue (TTM)

$184.91M

Gross Profit (TTM)

$125.31M

EBITDA (TTM)

$5.91M

Year Range

$0.80 - $3.14

Target Price

$7.25

Short %

6.86%

Short Ratio

4.42

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Akebia Therapeutics, Inc.

Performance

Performance Chart


Loading data...

S&P 500

Returns By Period

Akebia Therapeutics, Inc. (AKBA) returned 58.42% year-to-date (YTD) and 192.23% over the past 12 months. Over the past 10 years, AKBA returned -9.09% annually, underperforming the S&P 500 benchmark at 10.84%.


AKBA

YTD

58.42%

1M

23.87%

6M

46.12%

1Y

192.23%

3Y*

100.62%

5Y*

-23.70%

10Y*

-9.09%

^GSPC (Benchmark)

YTD

0.52%

1M

6.32%

6M

-1.44%

1Y

12.25%

3Y*

12.45%

5Y*

14.20%

10Y*

10.84%

*Annualized

Monthly Returns

The table below presents the monthly returns of AKBA, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202517.89%-17.41%3.78%25.52%24.90%58.42%
202435.48%-5.95%15.82%-31.15%-11.11%-8.93%35.29%12.32%-14.84%25.76%24.10%-7.77%53.23%
20239.19%33.76%-33.50%62.12%14.47%-12.02%82.51%-16.77%-17.99%-22.81%20.45%16.98%114.90%
2022-11.95%8.54%-66.76%-42.16%-10.91%-4.54%10.73%-6.83%-13.20%-19.51%6.29%113.31%-74.47%
202115.71%6.79%-2.17%-5.76%10.03%7.98%-34.83%19.03%-2.04%-0.35%-5.57%-16.61%-19.29%
202014.24%22.85%-14.54%6.86%43.70%16.67%-17.75%-6.80%-75.89%-11.55%49.10%-15.41%-55.70%
2019-0.36%32.12%12.50%-26.25%-26.32%8.76%-13.43%-1.43%-5.08%-4.85%68.63%0.48%14.29%
2018-0.61%-3.25%-33.36%-3.36%6.62%1.63%3.21%-20.29%7.55%-15.18%7.88%-31.56%-62.81%
2017-3.65%-0.10%-8.18%43.26%1.67%7.24%-8.21%26.91%17.50%-7.73%-14.27%-4.43%42.84%
2016-43.27%-0.41%23.42%4.22%-5.11%-16.05%19.65%-9.16%11.32%-16.91%14.49%20.91%-19.43%
2015-11.77%-9.83%19.98%-30.96%2.48%30.92%-8.65%-25.96%38.79%-7.66%20.29%20.41%11.00%
2014-26.73%24.59%-0.29%14.36%-20.33%1.67%-1.69%-41.44%-6.79%-3.64%-56.40%
Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 94, AKBA is among the top 6% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of AKBA is 9494
Overall Rank
The Sharpe Ratio Rank of AKBA is 9797
Sharpe Ratio Rank
The Sortino Ratio Rank of AKBA is 9393
Sortino Ratio Rank
The Omega Ratio Rank of AKBA is 9393
Omega Ratio Rank
The Calmar Ratio Rank of AKBA is 9191
Calmar Ratio Rank
The Martin Ratio Rank of AKBA is 9595
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Akebia Therapeutics, Inc. (AKBA) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Akebia Therapeutics, Inc. Sharpe ratios as of May 30, 2025 (values are recalculated daily):

  • 1-Year: 2.44
  • 5-Year: -0.25
  • 10-Year: -0.11
  • All Time: -0.21

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Akebia Therapeutics, Inc. compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

Dividend History


Akebia Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Akebia Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Akebia Therapeutics, Inc. was 99.14%, occurring on Nov 29, 2022. The portfolio has not yet recovered.

The current Akebia Therapeutics, Inc. drawdown is 89.68%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.14%Jun 23, 20142126Nov 29, 2022
-36.84%Mar 21, 201416Apr 11, 20145Apr 21, 201421
-21.82%Apr 22, 201420May 19, 201414Jun 9, 201434
-4.91%Jun 10, 20146Jun 17, 20143Jun 20, 20149
Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Akebia Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Akebia Therapeutics, Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 130.9% positive surprise.


-0.60-0.40-0.200.000.2020212022202320242025
0.02
-0.08
Actual
Estimate

Valuation

The Valuation section provides an overview of how Akebia Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for AKBA compared to other companies in the Biotechnology industry. AKBA currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for AKBA relative to other companies in the Biotechnology industry. Currently, AKBA has a P/S ratio of 4.1. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for AKBA in comparison with other companies in the Biotechnology industry. Currently, AKBA has a P/B value of 31.2. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items